MX2022004785A - Metodos y composiciones para el tratamiento del sindrome de rett. - Google Patents

Metodos y composiciones para el tratamiento del sindrome de rett.

Info

Publication number
MX2022004785A
MX2022004785A MX2022004785A MX2022004785A MX2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A
Authority
MX
Mexico
Prior art keywords
methods
rett syndrome
compositions
treatment
trofinetide
Prior art date
Application number
MX2022004785A
Other languages
English (en)
Inventor
Mona Darwish
James M Youakim
Lawrence Irwin Glass
Nancy Elizabeth Jones
Sean Paul Oosterholt
Oscar Della Pasqua
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of MX2022004785A publication Critical patent/MX2022004785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

En la presente se divulgan métodos de tratamiento del síndrome de Rett que comprenden administrar trofinetide a un sujeto que lo necesita en los que se proporciona una dosificación que puede reducir o evitar una subexposición, p. ej., en sujetos de peso corporal bajo, y/o proporcionar otros beneficios.
MX2022004785A 2019-10-28 2020-10-28 Metodos y composiciones para el tratamiento del sindrome de rett. MX2022004785A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US202063031201P 2020-05-28 2020-05-28
PCT/US2020/057627 WO2021086892A1 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of rett syndrome

Publications (1)

Publication Number Publication Date
MX2022004785A true MX2022004785A (es) 2022-05-16

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004785A MX2022004785A (es) 2019-10-28 2020-10-28 Metodos y composiciones para el tratamiento del sindrome de rett.

Country Status (14)

Country Link
US (1) US20220339138A1 (es)
EP (1) EP4051308A4 (es)
JP (1) JP2022553888A (es)
KR (1) KR20220106982A (es)
CN (1) CN115335071A (es)
AU (1) AU2020376801A1 (es)
BR (1) BR112022008095A2 (es)
CA (1) CA3156680A1 (es)
CL (1) CL2022001079A1 (es)
CO (1) CO2022007501A2 (es)
IL (1) IL292617A (es)
MX (1) MX2022004785A (es)
TW (1) TW202116300A (es)
WO (1) WO2021086892A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287750A1 (en) 2021-07-12 2023-01-19 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
PT2667715T (pt) * 2011-01-27 2017-10-19 Neuren Pharmaceuticals Ltd Tratamento de perturbações do espetro do autismo utilizando o ácido glicil-l-2-metilpropil-l-glutâmico
ES2741146T3 (es) * 2013-02-20 2020-02-10 The Board Of Supervisors Of The Louisiana State Univ Mechanical And Agricultural College Formulaciones farmacéuticas de nitrio y sus usos
PL3024463T3 (pl) * 2013-07-25 2020-10-05 Neuren Pharmaceuticals Limited Neuroprotekcyjne związki bicykliczne i sposoby ich zastosowania w leczeniu spektrum zaburzeń autystycznych i zaburzeń neurorozwojowych
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Also Published As

Publication number Publication date
EP4051308A1 (en) 2022-09-07
KR20220106982A (ko) 2022-08-01
CA3156680A1 (en) 2021-05-06
CL2022001079A1 (es) 2023-04-21
TW202116300A (zh) 2021-05-01
US20220339138A1 (en) 2022-10-27
BR112022008095A2 (pt) 2022-07-12
CO2022007501A2 (es) 2022-08-30
IL292617A (en) 2022-07-01
CN115335071A (zh) 2022-11-11
AU2020376801A1 (en) 2022-06-09
WO2021086892A1 (en) 2021-05-06
EP4051308A4 (en) 2023-08-23
JP2022553888A (ja) 2022-12-26

Similar Documents

Publication Publication Date Title
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2019012884A (es) Terapia de combinacion.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
ZA202202673B (en) Methods and compositions for treating endometriosis
MX2020012795A (es) Safinamida para el tratamiento de miotonia.
MX2022010628A (es) Composicion para la prevencion y tratamiento de la disbiosis.
MX2022001200A (es) Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico.